Sorted By:

Relevance


340B

PhRMA  |  From PhRMA

click here for even more information on 340B.
https://www.phrma.org/advocacy/340b

340B Spotlight: Hospital system adds voice to comments about flawed 340B program

PhRMA  |  Blog Post

Learn more at PhRMA.org/340B.
http://catalyst.phrma.orghttps://catalyst.phrma.org/340b-spotlight-hospital-system-adds-voice-to-comments-about-flawed-340b-program

340B Then & Now

PhRMA  |  Graphic

A closer look at how the 340B program has evolved since its creation in 1992.
https://www.phrma.org/graphic/340b-then-and-now

PhRMA Statement on 340B PAUSE Act

PhRMA  |  Press Release

“This legislation provides Congress with a much-needed opportunity to closely evaluate 340B and ways it can be fixed to the benefit of patients.”
https://www.phrma.org/press-release/phrma-statement-on-340b-pause-act

340B Spotlight: New pieces of legislation continue momentum to fix 340B program

PhRMA  |  Blog Post

Learn more at PhRMA.org/340B.
http://catalyst.phrma.org/340b-spotlight-new-pieces-of-legislation-continue-momentum-to-fix-340b-program

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

PhRMA  |  Blog Post

This markup becomes even more egregious, 79 percent, if the hospital was able to acquire the drug at the 340B discounted price.
http://catalyst.phrma.org/340b-spotlight-340b-hospitals-continue-to-benefit-from-consolidation-at-expense-of-patients

340B Spotlight: Audit findings show importance of increased oversight of 340B program

PhRMA  |  Blog Post

Learn more about the 340B program at PhRMA.org/340B.
http://catalyst.phrma.org/340b-spotlight-audit-findings-show-importance-of-increased-oversight-of-340b-program

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

PhRMA  |  Blog Post

Read the full BRG report here and learn more about 340B here.
http://catalyst.phrma.org/340b-spotlight-new-analysis-finds-340b-program-growth-continues-to-accelerate-despite-false-claims

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

PhRMA  |  Blog Post

Learn more at PhRMA.org/340B.
http://catalyst.phrma.org/340b-spotlight-icymi-ajc-looks-at-how-some-georgia-hospitals-are-profiting-off-340b

340B Drug Discount Program Pocket Card

PhRMA  |  Fact Sheet

Clinics eligible for the 340B program as part of a federal grant program are required to reinvest any additional resources into services for the vulnerable communities they serve, while current rules allow hospitals participating in the program to profit by reselling discounted medicines with no requirement to ensure patients benefit from the discounts.
https://www.phrma.org/fact-sheet/340b-drug-discount-program-pocket-card

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

PhRMA  |  Blog Post

To learn more about the 340B program, visit PhRMA.org/340B.
http://catalyst.phrma.org/340b-spotlight-icymi-340b-hearing-new-reports-highlight-growing-need-for-program-reform

340B 101

PhRMA  |  Report

Download the deck to learn more about the 340B program.
https://www.phrma.org/report/340b-101

Fact Check Friday: The truth about the cost of 340B to patients

PhRMA  |  Blog Post

For more information about the 340B program, visit PhRMA.org/340B.
http://catalyst.phrma.orghttps://catalyst.phrma.org/fact-check-friday-the-truth-about-the-cost-of-340b-to-patients

PhRMA Statement on HELP ACT

PhRMA  |  Press Release

There has long been bipartisan support for fixing 340B, including recently introduced bipartisan legislation in the House, and PhRMA looks forward to working with all stakeholders to keep this momentum going.”
https://www.phrma.org

340B Spotlight: Myth vs. Fact

PhRMA  |  Graphic

Congress created the 340B program in 1992 to help health care safety-net facilities that serve a large proportion of needy or uninsured patients have access to discounted prescription medicines.
https://www.phrma.org/graphic/340b-spotlight-myth-vs-fact

Legislative and Regulatory History of the Evolution of 340B Program

PhRMA  |  Fact Sheet

The 340B program was created by Congress in 1992 to help vulnerable or uninsured patients access prescription medicines at safety net facilities.
https://www.phrma.org/fact-sheet/legislative-and-regulatory-history-of-the-evolution-of-340b-program

PhRMA Special 301 Submission 2018

PhRMA  |  Policy Paper

Established by the Trade Act of 1974, the Special 301 review gives the Administration a critical tool to address damaging market access and intellectual property barriers abroad that harm America’s leading innovative and creative industries and the more than 45 million jobs they support across the country.
https://www.phrma.org

340B Program in urgent need of expanded Congressional and administrative oversight, reform

PhRMA  |  Press Release

As additional evidence that the program has expanded beyond true safety net hospitals, the analysis revealed that about one-fifth of 340B hospitals provide 80 percent of all charity care delivered by 340B hospitals.
https://www.phrma.org/press-release/340b-program-in-urgent-need-of-expanded-congressional-and-administrative-oversight-reform

340B Drug Purchases and Population without Drug Coverage

PhRMA  |  Graphic

Drug purchases through the 340B program will continue to rise, at the same time the share of the population without prescription drug coverage will nearly drop in half.
https://www.phrma.org/graphic/trends-in-340b-drug-purchases-and-percent-of-total-population-without-prescription-drug-coverage

How much are hospitals marking up the price of medicines? The answer may surprise you.

PhRMA  |  Blog Post

On average, 340B prices are significantly lower than the average sales price (ASP) – about 22.5 percent below ASP, according to the Medicare Payment Advisory Commission (MedPAC) – which is why medicines purchased by hospitals at 340B prices could have even larger margins.
http://catalyst.phrma.org/how-much-are-hospitals-marking-up-the-price-of-medicines-the-answer-may-surprise-you

New Analysis: 340B Program Shifting Delivery of Physician-Administered Medicines to More Expensive Hospital Settings

PhRMA  |  Press Release

To learn more about the 340B program and ways it could be fixed, visit PhRMA.org/340B.
https://www.phrma.org/press-release/new-analysis-340b-program-shifting-delivery-of-physician-administered-medicines-to-more-expensive-hospital-settings

PhRMA Special 301 Submission 2017

PhRMA  |  Policy Paper

The Special 301 statute calls upon the Office of the United States Trade Representative (USTR) to address in its review foreign country practices that deny fair and equitable market access to U.S. persons that rely upon intellectual property (IP) protection.
https://www.phrma.org/phrma-special-301-submission

340B: Past and Present

Chartpack  |  From Our Network

When it was created in 1992, 340B was envisioned as a small program however insufficient guidance, historically weak oversight, and other factors have led to dramatic program growth, driven by the participation of large hospitals in the 340B program.
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/340b-past-and-present

340B Spotlight: A Look at 340B Purchases

PhRMA  |  Blog Post

By 2019, the Berkeley Research Group projects the 340B program will account for 8.0 percent of sales.
http://catalyst.phrma.org/340b-spotlight-a-look-at-340b-purchases

340B Spotlight: A lack of charity care among 340B hospitals

PhRMA  |  Blog Post

  For more check out our chart pack or stay up-to-date on the latest 340B news with our 340B Spotlight posts.
http://catalyst.phrma.org/340b-spotlight-a-lack-of-charity-care-among-340b-hospitals

You have reviewed the first 25 results out of 438. Each page contains 25 results. You're on page 1.

prev 1 2 3 4 5 6 next